Compare IVZ & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVZ | SNN |
|---|---|---|
| Founded | 1935 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 14.3B |
| IPO Year | 2014 | N/A |
| Metric | IVZ | SNN |
|---|---|---|
| Price | $25.36 | $36.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 3 |
| Target Price | $27.47 | ★ $35.75 |
| AVG Volume (30 Days) | ★ 5.2M | 830.4K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.33% | 2.01% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,314,100,000.00 | N/A |
| Revenue This Year | N/A | $7.68 |
| Revenue Next Year | $5.70 | $5.47 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | ★ 2.98 | N/A |
| 52 Week Low | $11.60 | $23.91 |
| 52 Week High | $29.61 | $38.79 |
| Indicator | IVZ | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 57.33 |
| Support Level | $25.12 | $36.13 |
| Resistance Level | $27.53 | $37.26 |
| Average True Range (ATR) | 0.96 | 0.60 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 24.70 | 67.63 |
Invesco provides investment-management services to retail (70% of managed assets) and institutional (30%) clients. At the end of November 2025, the firm had $2.154 trillion in assets under management spread among its equity (62% of AUM), balanced (3%), fixed-income (20%), alternative investment (6%), and money market (9%) operations. Passive products account for close to half of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 31% of its AUM sourced from Europe, Africa, and the Middle East (16%) and Asia (15%).
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.